ALK-Altered Non-Small Cell Lung Cancer
GSKGSKCatalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Neladalkib (NVL-655) (ALK Inhibitor) in ALK-Altered Non-Small Cell Lung Cancer. The expected timing is based on the latest available company guidance and may change.
07/22/26:- FDA decision for neladalkib in ALK-altered NSCLC due November 27, 2026.
Verification
Confirm timing and program details against the company announcement or filing.